Of note, low-dose IL-2-mediated expansion of Tregs is currently being investigated in a phase I/II clinical trial for prevention of recurrent MI in patients with stable ischemic disease or acute coronary syndromes (58). The gene discussed is IL2; the disease is acute coronary syndrome.